Skip to main content
. 2020 May 18;15(5):e0233176. doi: 10.1371/journal.pone.0233176

Fig 3. Role of K+-channels within the relaxant effect of levosimendan in human PCLS.

Fig 3

A) Inhibition of KATP-channels (glibenclamide) in ET-1 pre-constricted PAs: ○ 100 nM ET-1 / 10 μM glibenclamide (n = 6); ● 100 nM ET-1 / 10 μM glibenclamide / levosimendan (n = 6); ● 100 nM ET-1 / levosimendan (n = 6). B) Inhibition of KV-channels (5-aminopyridine) in ET-1 pre-constricted PAs: ○ 100 nM ET-1 / 5 mM 5-aminopyridine (n = 6); ● 100 nM ET-1 / 5 mM 5-aminopyridine / levosimendan (n = 6); ● 100 nM ET-1 / levosimendan (n = 6). C) Inhibition of BKCa2+-channels (iberiotoxin) in ET-1 pre-constricted PAs: ○ 100 nM ET-1 / 100 nM iberiotoxin (n = 5); ● 100 nM ET-1 / 100 nM iberiotoxin / levosimendan (n = 5s); ● 100 nM ET-1 / levosimendan (n = 5). D) Effect of inhibition of K+-channels on the contractile effect of ET-1. A-C: Statistics was performed by the comparison of EC50 values. D: Statistic was performed by an one-way ANOVA. P<0.05 are considered as significant: * p<0.05, ** p<0.01 and *** p<0.001.